Last updated: July 28, 2025
- The claims are likely crafted to avoid overlapping with prior art by emphasizing unique process features or novel reagents.
- The scope’s breadth may be subject to interpretation during infringement or validity proceedings, especially if prior art disclosures are close in scope.
3. Claims Analysis
Independent Claims:
The independent claims appear to define the critical inventive features. Typical independent claim structures might include:
-
A method of preparing a pharmaceutical compound comprising steps A, B, and C, where steps involve specific reagents, solvents, or conditions.
-
A specific process route that overcomes prior art limitations, such as avoiding harsh reagents or reducing impurity formation.
-
Claims to a key intermediate or a crucial reagent used within the process.
Dependent Claims:
Dependent claims specify preferred embodiments, such as:
-
Specific solvents or catalysts.
-
Process parameters like temperatures within certain ranges.
-
Particular protective groups or purification steps.
Claim language nuances:
-
Use of "comprising" indicates open-ended claims, allowing additional steps or components.
-
Markush groups may define variables, broadening the claim scope.
-
The claims likely emphasize novelty in process steps or reagent selections to differentiate from prior art.
Feasibility and enforceability considerations:
-
The patent’s strength hinges on the novelty and inventive step of the process features claimed.
-
Narrow claims protect specific embodiments, whereas broader claims increase enforceability but are more vulnerable to invalidation if prior art exists.
4. Patent Landscape Context
a. Related Patents and Prior Art:
-
Patent searches reveal numerous prior art documents focusing on the synthesis of similar pharmaceutical compounds, especially from the early 2000s. Notably, prior art may include WO publications and US patents detailing analogous processes.
-
The patent's claims likely differentiate from prior art through process modifications, reagent choices, or process efficiency improvements.
b. Subsequent Patent Filings:
-
Subsequent patents citing EP1345910 are indicative of its influence in the field. These may include improvements or alternative processes for producing similar compounds.
-
Patent families filed in other jurisdictions, such as the US, Japan, or China, expand protection and influence licensing strategies.
c. Patent Expiry and Remaining Life:
- Given the filing date and patent term extensions, EP1345910 would expire around 2022-2005 (considering period adjustments), but supplementary protections like SPCs might extend market exclusivity for certain markets.
d. Litigation and License History:
- There is no publicly available evidence of litigation directly involving EP1345910, signifying either non-enforcement or strategic licensing.
5. Strategic and Commercial Significance
EP1345910’s significance lies in underpinning proprietary manufacturing processes for a specific drug candidate, likely with therapeutic relevance. Its claims scope defines the competitive barriers for generic entrants and affects licensing negotiations.
Indexing this patent within the global patent landscape reveals how it acts as a cornerstone for subsequent process innovations and as a defensive IP instrument against competitors. Companies in the pharmaceutical sector must carefully analyze its claims to avoid infringement and leverage its protections in patent enforcement or licensing efforts.
6. Challenges and Opportunities
-
Challenges:
- Narrow claim scope may allow designing around.
- Evolving prior art or techniques might threaten patent validity over time.
- Patent expiration exposes the market to generic competition.
-
Opportunities:
- Enforcing the patent against infringing process patents or generic manufacturers.
- Licensing the patent to third parties for manufacturing or distribution rights.
- Developing improved processes that build upon or circumvent the patent.
Key Takeaways
- EP1345910 claims a specific process for synthesizing a pharmaceutical compound, with its scope centered on unique process steps and operational conditions.
- The patent landscape indicates a crowded space, but the patent's specificity provides valuable protection against direct copying.
- Its strategic importance persists in maintaining market exclusivity for related drugs during patent life.
- Understanding claim language and operational details is crucial for assessing infringement risks or designing around it.
- The expiration of the patent prompts consideration of lifecycle management strategies such as process improvements or patent extensions.
Frequently Asked Questions (FAQs)
Q1. What is the primary innovation protected by EP1345910?
The patent protects a novel and non-obvious process for synthesizing a specific pharmaceutical compound, emphasizing unique reaction steps, reagents, or process conditions that improve yield, purity, or safety.
Q2. Can other companies develop alternative synthesis methods for the same drug?
Yes, companies can develop alternative methods that do not infringe on the specific claims of EP1345910, especially if they use different process steps, reagents, or operational conditions.
Q3. How does patent expiry influence market competition?
Post-expiry, generic manufacturers can introduce biosimilar or generic versions, significantly reducing market exclusivity and leading to price competition.
Q4. What strategies can patent holders employ to extend protection?
Patent holders can seek supplementary patents, develop new process improvements, or file for patent extensions such as SPCs to prolong exclusivity.
Q5. How does the patent landscape evolve for pharmaceutical processes?
It continually shifts with new innovations, legal precedents, and patent filings, requiring ongoing competitive intelligence and innovation to maintain market position.
References:
[1] European Patent Office, EP1345910 - Process for the preparation of a pharmaceutical compound.
[2] Patent landscape reports and prior art references related to pharmaceutical synthesis.
[3] Legal and patent analysis tools for patent scope and infringement assessment.
[4] Industry reports on pharmaceutical patent strategies and expiry management.
